Interferon beta: the current position.
Treatments that reduce disease activity in multiple sclerosis are now available, but it is not known how these agents will modify the development of disability in the long term. Published trials of the use of interferon beta failed to detect any clinically relevant reduction in accumulation of disability during the study period. Should patients therefore be prescribed these compounds?
Boothman
B R
BR
Department of Neurology, Royal Preston Hospital.
D000917:Antibody Formation; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D019317:Evidence-Based Medicine; D006801:Humans; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome
D016899:Interferon-beta